Arch Therapeutics (OTCMKTS:ARTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage presently has a $0.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 22.95% from the stock’s current price.

According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “

A number of other research analysts have also weighed in on the stock. ValuEngine lowered shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Arch Therapeutics in a research note on Monday, September 18th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $2.31.

Arch Therapeutics (OTCMKTS ARTH) remained flat at $$0.61 during trading hours on Friday. The company’s stock had a trading volume of 226,620 shares, compared to its average volume of 381,553. Arch Therapeutics has a one year low of $0.41 and a one year high of $0.89.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/arch-therapeutics-arth-lifted-to-buy-at-zacks-investment-research.html.

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arch Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.